Breathe Well Live Well
|
New drug 'stops common cold asthma deaths'
West Sussex Gazette The news is based solely on a press release, which gives some information about the findings of an early-stage clinical trial of a new, unlicensed asthma drug called SNG001. The press release describes research that was conducted in a total of 134 … |
View full post on asthma – Google News
| Related Articles |
On-off pulsed oral drug-delivery systems: a possible tool for drug delivery in chronotherapy.
Ther Deliv. 2011 Sep;2(9):1199-214
Authors: Tran TH, Lee BJ
Abstract
Circadian rhythms regulate most body functions and are important factors to consider when administering drugs. The existence of circadian rhythms in nature and their influences on human biological systems have given rise to the concept of chronotherapy, which is the science of delivering drugs in a synchronized manner with the rhythm-dependent circadian variation inherent in the human body. The safety and efficacy of a drug can be improved by matching the peak plasma concentration during a 24 h period of the rhythms. An on-off pulsed (pulsatile or time-controlled) release drug-delivery system offers rapid and transient release; stepwise release; and the sustained release of a certain amount of drug within a short time period after a predetermined off-release period according to the circadian rhythm of disease states. These systems deliver the drug at the right time and at an appropriate dosage and are the best approach for chronotherapy. These systems show promise for the optimal therapy of chronic diseases such as asthma, hypertension, myocardial infarction and arthritis, which show a circadian dependency. Various technologies have been adopted to mimic circadian rhythms in physiological functions and diseases. This review focuses on the basic concept of circadian rhythm, chronotherapy and recent advances in the development of on-off pulsed oral drug-delivery systems for optimal therapy.
PMID: 22833913 [PubMed – in process]
View full post on pubmed: asthma
|
New drug 'stops common cold asthma deaths'
Boness Today The news is based solely on a press release, which gives some information about the findings of an early-stage clinical trial of a new, unlicensed asthma drug called SNG001. The press release describes research that was conducted in a total of 134 … |
View full post on asthma – Google News
|
New drug 'stops common cold asthma deaths'
Tyrone Times The news is based solely on a press release, which gives some information about the findings of an early-stage clinical trial of a new, unlicensed asthma drug called SNG001. The press release describes research that was conducted in a total of 134 … |
View full post on asthma – Google News
|
New drug 'stops common cold asthma deaths'
Gainsborough Standard The news is based solely on a press release, which gives some information about the findings of an early-stage clinical trial of a new, unlicensed asthma drug called SNG001. The press release describes research that was conducted in a total of 134 … |
View full post on asthma – Google News
|
Cairns-based asthma cure drug trial receives US funding
The Cairns Post CAIRNS scientists who created a ground-breaking drug that cures asthma in mice have received financial backing from a US pharmaceutical giant to further develop it for human trials. |
View full post on asthma – Google News
|
GSK, Theravance seek FDA, European approval of COPD/asthma drug
Upstart (blog) Theravance Inc. and partner GlaxoSmithKline are asking regulators to approve a once-a-day… GSK and Theravance Announce Regulatory Submissions for FF/VI in the US and … GSK, Theravance hit up regulators for approval of key asthma/COPD drug GSK seeks approval for drug candidates |
View full post on asthma – Google News
 The Guardian |
Drug Company GlaxoSmithKline Puts American Values to Shame
Huffington Post The asthma drug Advair became a never-ending blockbuster with sales of $7.8 billion in 2010 and predictions that the COPD drug market, which Advair leads, will reach $13.4 billion worldwide in 2020. The success is especially remarkable in regard to the … GlaxoSmithKline pays $3 billion in healthcare fraud settlement State receives $1.7M from largest health-care fraud settlement in US history |
View full post on asthma – Google News
|
SkyePharma's Asthma Drug Finally Approved in Europe
Equities.com LONDON – The asthma treatment Flutiform finally won the seal of the European Commission last week, more than 12 years after SkyePharma plc set its sights on what it thought would be the relatively straightforward development of a combination product … Small caps: Drug OK lifts SkyePharma |
View full post on asthma – Google News
|
Glaxo Settlement Pulls Back Curtain On Drug Marketing
NPR (blog) The government alleged that Glaxo promoted Advair, an asthma remedy combining two drugs, for use as a first-choice treatment for just about anybody with asthma. The Food and Drug Administration, concerned about risks, took a much narrower view and … |
View full post on asthma – Google News